<scp>Anti‐CD38</scp> monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping-Reference-Cited by-同舟云学术

Anti‐CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping

Published:2022-10-14 Issue:11 Volume:62 Page:2334-2348
ISSN:0041-1132
Container-title:Transfusion
language:en
Short-container-title:Transfusion

Author:

Chami Btissam¹^ORCID,Okuda Makoto²,Moayeri Morvarid³^ORCID,Pirenne France¹^ORCID,Hidaka Yoko²,Nambiar Ashok³,Song Zhili⁴,Bedel Olivier⁴⁵,Zhang Bailin⁴,Hopke Joern⁶,Deng Gejing⁴,Zhu Chen⁴,Macé Sandrine⁷,Chiron Marielle⁷,Adrian Francisco⁴⁸,Fukao Taro⁴,Basile Frank G.⁴⁹,Martin Thomas¹⁰

Affiliation:

1. Établissement Français du Sang Île‐de‐France Paris France

2. Toho University Medical Center Omori Hospital Tokyo Japan

3. Transfusion Service, University of California San Francisco San Francisco California USA

4. Sanofi, Global Oncology Cambridge Massachusetts USA

5. Worked for Sanofi at the time of study, currently at Amgen Thousand Oaks California USA

6. Sanofi, Large Molecule Research Cambridge Massachusetts USA

7. Sanofi, Research and Development Paris France

8. Worked for Sanofi at the time of the study, currently at HiFiBio Therapeutics Cambridge Massachusetts USA

9. Worked for Sanofi at the time of the study, currently at Nurix Therapeutics San Francisco California USA

10. Helen Diller Family Comprehensive Cancer Center University of California San Francisco San Francisco California USA

Funder

Sanofi

Sanofi Genzyme

Publisher

Wiley

Subject

Hematology,Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/trf.17137

Reference31 articles.

1. Multiple myeloma epidemiology and survival: A unique malignancy

2. Interference of daratumumab with pretransfusion testing, mimicking a high-titer, low avidity like antibody

3. SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide

4. Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab

5. Sarclisa (isatuximab‐irfc) injection for intravenous use.Prescribing information. sanofi‐aventis U.S. LLC. Available from:https://products.sanofi.us/Sarclisa/sarclisa.pdf. Accessed July 21 2022.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acquired CD38 gene deletion as a mechanism of tumor antigen escape in multiple myeloma;Blood Advances;2023-11-30

2. Evorpacept-Induced Interference and Application of a Novel Mitigation Agent, Evo-NR, in Pretransfusion Testing;Transfusion Medicine and Hemotherapy;2023-10-25

3. Long-term storage protocol of reagent red blood cells treated with 0.01M dithiothreitol (DTT) for pre-transfusion testing of patients receiving anti-CD38 therapy, daratumumab;Hematology;2023-03-09